Clinical trials: Severe Respiratory Distress
Respiratory Distress Syndrome, Positive-Pressure Respiration
Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability
This observational study will explore the effects of PEEP and position on regional lung ventilation-perfusion mismatch by electrical impedance tomography (EIT) in moderate-to-severe ARDS patients with different lung…
- Conditions
- Respiratory Distress Syndrome, Positive-Pressure Respiration, Mechanical Ventilation
- Trial name
- NCT06430554
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongda Hospital
Acute Respiratory Distress Syndrome, COVID-19
Predictors of Severe COVID-19 Outcomes
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes…
- Trial name
- PRESCO (NCT04388813)
- Where
- 8 sites in United States
- Volunteers
- 494 people
- Sponsor
- Verily Life Sciences LLC
COVID-19, Severe Respiratory Distress Syndrome
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19.
- Conditions
- COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
- Trial name
- NCT07466524
- Testing
- suPARnostic® TurbiLatex Assay on Roche cobas c501
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- ViroGates A/S
ARDS (Acute Respiratory Distress Syndrome)
Comparative Study Between Airway Pressure Release Ventilation and Pressure Regulated Volume Control (PRVC) in Protective Lung Strategy as a Recruitment Maneuver for Severe ARDS Mechanically Ventilated Patients Using Lung Ultrasound Score
The aim of this study is to elaborate on the effectiveness of recruitment maneuver by airway pressure release ventilation (APRV) as an open lung ventilatory strategy in comparison with PRVC mode in lung protective strategy…
- Trial name
- NCT07231107
- Testing
- Lung ultrasound
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Influenza, Avian Influenza
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths…
- Conditions
- Influenza, Avian Influenza, Severe Influenza
- Trial name
- NCT00298233
- Testing
- Oseltamivir
- Where
- 12 sites in Singapore, Thailand and 1 more
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution to the lack of ICU beds and increasing deaths day after day.
- Conditions
- Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections, ARDS, Human
- Trial name
- MP-C19 (NCT04323592)
- Testing
- Methylprednisolone, standard care
- Where
- Italy
- Volunteers
- 173 people
- Sponsor
- University of Trieste
Severe Eosinophilic Asthma, Psychological Distress
Severe Asthma, MepolizumaB and Affect: SAMBA Study
This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners.
- Conditions
- Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression
- Trial name
- SAMBA (NCT04680611)
- Testing
- no study intervention. Patients receive standard clinical care
- Where
- 6 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
COVID-19, SARS-CoV-2 Infection
Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus (SARS-CoV-2) that can progress to severe disease requiring hospitalization and oxygen support in around14% of the cases…
- Trial name
- NCT04410107
- Testing
- Lung Function tests, Exercise capacity, Exercise physiology
- Where
- 5 sites in Brazil
- Volunteers
- 144 people
- Sponsor
- Federal University of Rio Grande do Sul
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Covid19
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- NCT06729593
- Testing
- Remdesivir, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, ARDS
Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome
Non-invasive ventilation can allow to avoid intubation and improve outcomes in moderate-to-severe COVID-19-associated acute respiratory distress-syndrome (ARDS).
- Trial name
- COVID-NIV (NCT04667923)
- Testing
- Respiratory monitoring, Respiratory muscles ultrasound, Electro impedance tomography
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Moderate Respiratory Distress, Severe Respiratory Distress
High Flow Nasal Oxygen Therapy an Implementation Study in Pediatric Wards
The purpose of this study is to prospectively evaluate the process of implementing HFNO in several MSF projects, varying according to geographical and programmatic contexts, population, health structures, human resources, and…
- Trial name
- HFNO (NCT06715423)
- Where
- Afghanistan
- Volunteers
- 960 people
- Sponsor
- Epicentre
Respiratory Distress Syndrome, Mechanical Ventilation
Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19)
This is a prospective, randomized, single-center, open-label controlled trial, designed to compare the efficacy of two ventilation strategies (Low Tidal Volume and positive end-expiratory pressure (PEEP) based on the Acute…
- Conditions
- Respiratory Distress Syndrome, Mechanical Ventilation, SARS (Severe Acute Respiratory Syndrome)
- Trial name
- COVEN (NCT04497454)
- Testing
- EIT-Group, ARDSNet
- Where
- Brazil
- Volunteers
- 128 people
- Sponsor
- University of Sao Paulo General Hospital
COVID-19
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
- Trial name
- SARPAC (NCT04326920)
- Testing
- Sargramostim, Control
- Where
- 4 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- University Hospital, Ghent
Hypoxia, Respiratory Acidosis
FIRST-line Support for Assistance in Breathing in Children (FIRST-ABC) Feasibility Study
A feasibility study to inform the design and conduct of a randomised controlled trial of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in critically ill…
- Conditions
- Hypoxia, Respiratory Acidosis, Moderate/Severe Respiratory Distress
- Trial name
- FIRST-ABC (NCT02612415)
- Testing
- Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula, Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure
- Where
- 3 sites in United Kingdom
- Volunteers
- 121 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Intensive Care Units, ARDS, Human
Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections
Severe Covid-19 (Coronavirus Disease 2019) infections generate major but inappropriate production of cytokines and, in some cases, generate anti-IFN (Interferon) auto-antibodies, inducing acute respiratory distress syndrom…
- Conditions
- Intensive Care Units, ARDS, Human, Covid19
- Trial name
- CovidEP (NCT04751643)
- Testing
- Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3), Usual treatments in intensive care unit according to the current state of knowledge
- Where
- 8 sites in France
- Volunteers
- 21 people
- Sponsor
- Hospices Civils de Lyon
Dyspnea
Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU
Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause.
- Trial name
- RECOVER (NCT04569266)
- Testing
- Specific exercise rehabilitation treatment, No specific exercise rehabilitation treatment
- Where
- 3 sites in France
- Volunteers
- 63 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Acute Respiratory Distress Syndrome, ARDS
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with…
- Trial name
- NCT05354141
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 32 sites in United States
- Volunteers
- 970 people
- Sponsor
- Direct Biologics, LLC
Acute Respiratory Distress Syndrome
Ultra Protective Ventilation Without Extracorporeal Circulation in Severe ARDS Patients (VT4ARDS)
Despite the use of protective ventilation, neuromuscular blocking agent and prone position, ARDS mortality remains high (30%-50%) in observational studies, and pneumothorax rate in randomized controlled trial remains stable…
- Trial name
- VT4ARDS (NCT02816372)
- Testing
- Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Hospices Civils de Lyon